AMARIN CORP PLC\UK Revenue, Net (Deprecated 2018-01-31)
AMARIN CORP PLC\UK (AMRN) reported Revenue, Net (Deprecated 2018-01-31) of $53.87 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2018-02-27
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $53.87M, a 39.20% increase year-over-year.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $47.36M, a 44.68% increase year-over-year.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $45.24M, a 36.63% increase year-over-year.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $34.64M, a 35.60% increase year-over-year.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for fiscal 2015 was $81.76M, a 50.84% increase from fiscal 2014.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for fiscal 2014 was $54.20M, a 105.69% increase from fiscal 2013.
- AMARIN CORP PLC\UK revenue, net (deprecated 2018-01-31) for fiscal 2013 was $26.35M.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $53.87M 10-K · filed 2018-02-27 | $101.23M derived: sum of 2 quarters · filed 2018-02-27 | $146.47M derived: sum of 3 quarters · filed 2018-02-27 | $181.10M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-09-30 | $47.36M 10-K · filed 2018-02-27 | $92.60M derived: sum of 2 quarters · filed 2018-02-27 | $127.24M derived: sum of 3 quarters · filed 2018-02-27 | $165.93M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-06-30 | $45.24M 10-K · filed 2018-02-27 | $79.88M derived: sum of 2 quarters · filed 2018-02-27 | $118.57M derived: sum of 3 quarters · filed 2018-02-27 | $151.31M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-03-31 | $34.64M 10-K · filed 2018-02-27 | $73.33M derived: sum of 2 quarters · filed 2018-02-27 | $106.07M derived: sum of 3 quarters · filed 2018-02-27 | $139.18M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-12-31 | $38.70M 10-K · filed 2018-02-27 | $71.43M derived: sum of 2 quarters · filed 2018-02-27 | $104.54M derived: sum of 3 quarters · filed 2018-02-27 | $130.08M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-09-30 | $32.73M 10-K · filed 2018-02-27 | $65.84M derived: sum of 2 quarters · filed 2018-02-27 | $91.39M derived: sum of 3 quarters · filed 2018-02-27 | $118.02M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $33.11M 10-K · filed 2018-02-27 | $58.65M derived: sum of 2 quarters · filed 2018-02-27 | $85.29M derived: sum of 3 quarters · filed 2018-02-27 | $106.77M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $25.54M 10-K · filed 2018-02-27 | $52.18M derived: sum of 2 quarters · filed 2018-02-27 | $73.66M derived: sum of 3 quarters · filed 2018-02-27 | $91.37M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $26.63M 10-K · filed 2017-03-01 | $48.12M derived: sum of 2 quarters · filed 2017-03-01 | $65.82M derived: sum of 3 quarters · filed 2017-03-01 | $81.76M 10-K · filed 2016-02-25 |
| 2015-09-30 | $21.48M 10-K · filed 2017-03-01 | $39.19M derived: sum of 2 quarters · filed 2017-03-01 | $55.12M 10-Q · filed 2015-11-04 | $71.60M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $17.71M 10-K · filed 2017-03-01 | $33.64M 10-Q · filed 2015-08-06 | $50.12M derived: sum of 3 quarters · filed 2017-03-01 | $64.27M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $15.93M 10-K · filed 2017-03-01 | $32.41M derived: sum of 2 quarters · filed 2017-03-01 | $46.56M derived: sum of 3 quarters · filed 2017-03-01 | $59.17M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $16.48M 10-K · filed 2016-02-25 | $30.63M derived: sum of 2 quarters · filed 2016-02-25 | $43.23M derived: sum of 3 quarters · filed 2016-02-25 | $54.20M 10-K · filed 2016-02-25 |
| 2014-09-30 | $14.15M 10-K · filed 2016-02-25 | $26.75M derived: sum of 2 quarters · filed 2016-02-25 | $37.72M 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $12.61M 10-K · filed 2016-02-25 | $23.57M 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | $10.97M 10-K · filed 2016-02-25 | |||
| 2013-12-31 | $26.35M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |